Monte Rosa reports positive Phase 1 GFORCE-1 results for MRT-8102 in elevated CVD-risk subjects
Bitget2026/10/01 11:05- Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102 in obese subjects with elevated cardiovascular risk.
- Findings were presented now, with a conference call and webcast scheduled for today.
- Treatment lowered multiple inflammatory and clotting-related disease drivers toward levels seen in healthy volunteers, supporting its proposed cardiovascular rationale.
- Safety profile looked comparable to placebo over dosing and follow-up, with no serious adverse events reported.
- Phase 2 studies are planned in coronary artery disease in H1 2027, with additional mid-stage trials in gout and hidradenitis suppurativa.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin closed above the 50-week moving average on Thursday.
Morgan Stanley comments on Coherent (COHR.US) Q1 financial report: not perfect but "good enough", the real highlight is the 20 billions USD long-term contract
Morgan Stanley has released its commentary on Coherent (COHR.US) following the company’s fiscal Q1 2027 earnings report, maintaining an "Equal-weight" rating and a target price of $325.
Nasdaq’s Staking Move: This Altcoin ETF News Stands Out from the Market! Here Are the Details
AI transformation potential does not equal investment returns! Plato Asset Management says the market is confusing two major logics, Nasdaq's plunge is just a "reality test"
David Allen, Head of Long/Short Strategies at Plato Investment Management, stated in an interview that Thursday's US stock market sell-off was the result of investors conflating the transformative potential of artificial intelligence (AI) with the actual investment return argument.
Crypto prices
More
